tarpeyohcpprod.prod.acquia-sites.com Open in urlscan Pro
3.231.20.35 Public Scan

Back to summary
URL:
https://tarpeyohcpprod.prod.acquia-sites.com/
Submission: On December 24 via api (December 24th 2023, 5:36:30 pm UTC) from US — Scanned from US
Form analysis
0 forms found in the DOM

Text Content

Skip to main content


MAIN NAVIGATION

Skip to main content
 * Download an enrollment form for TARPEYO Touchpoints
 * MECHANISM
   * MOD
   * MOA
 * TECHNOLOGY
 * EFFICACY
   * STUDY DESIGN
   * UPCR
   * eGFR
 * SAFETY
 * DOSING
 * ACCESS AND SUPPORT
 * RESOURCES
 * REQUEST A REP

Download an enrollment form for TARPEYO TouchpointsTM
Indication

TARPEYO® is a corticosteroid indicated to reduce proteinuria in adults with
primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease
progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.

This indication is approved under accelerated approval based on a reduction in
proteinuria. It has not been established whether TARPEYO slows kidney function
decline in patients with IgAN. Continued approval for this indication may be
contingent upon verification and description of clinical benefit in a
confirmatory clinical trial.

Important Safety Information


CONTRAINDICATIONS: 

TARPEYO is contraindicated in patients with hypersensitivity to budesonide or
any of the ingredients of TARPEYO. Serious hypersensitivity reactions, including
anaphylaxis, have occurred with other budesonide formulations.

Warnings and Precautions


HYPERCORTICISM AND ADRENAL AXIS SUPPRESSION: 

When corticosteroids are used chronically, systemic effects such as
hypercorticism and adrenal suppression may occur. Corticosteroids can reduce the
response of the hypothalamus-pituitary-adrenal (HPA) axis to stress. In
situations where patients are subject to surgery or other stress situations,
supplementation with a systemic corticosteroid is recommended. When
discontinuing therapy [see Dosing and Administration] or switching between
corticosteroids, monitor for signs of adrenal axis suppression.

Patients with moderate to severe hepatic impairment (Child-Pugh Class B and C,
respectively) could be at an increased risk of hypercorticism and adrenal axis
suppression due to an increased systemic exposure to oral budesonide. Avoid use
in patients with severe hepatic impairment (Child-Pugh Class C). Monitor for
increased signs and/or symptoms of hypercorticism in patients with moderate
hepatic impairment (Child-Pugh Class B).


RISKS OF IMMUNOSUPPRESSION: 

Patients who are on drugs that suppress the immune system are more susceptible
to infection than healthy individuals. Chicken pox and measles, for example, can
have a more serious or even fatal course in susceptible patients or patients on
immunosuppressive doses of corticosteroids. Avoid corticosteroid therapy in
patients with active or quiescent tuberculosis infection; untreated fungal,
bacterial, systemic viral, or parasitic infections; or ocular herpes simplex.
Avoid exposure to active, easily transmitted infections (eg, chicken pox,
measles). Corticosteroid therapy may decrease the immune response to some
vaccines.


OTHER CORTICOSTEROID EFFECTS: 

TARPEYO is a systemically available corticosteroid and is expected to cause
related adverse reactions. Monitor patients with hypertension, prediabetes,
diabetes mellitus, osteoporosis, peptic ulcer, glaucoma, cataracts, a family
history of diabetes or glaucoma, or with any other condition in which
corticosteroids may have unwanted effects.


ADVERSE REACTIONS: 

In clinical studies, the most common adverse reactions with TARPEYO (occurring
in ≥5% of TARPEYO patients and ≥2% higher than placebo) were hypertension (16%),
peripheral edema (14%), muscle spasms (13%), acne (11%), dermatitis (7%), weight
increase (7%), dyspnea (6%), face edema (6%), dyspepsia (5%), fatigue (5%), and
hirsutism (5%).


DRUG INTERACTIONS: 

Budesonide is a substrate for CYP3A4. Avoid use with potent CYP3A4 inhibitors,
such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir,
erythromycin, and cyclosporine. Avoid ingestion of grapefruit juice with
TARPEYO. Intake of grapefruit juice, which inhibits CYP3A4 activity, can
increase the systemic exposure to budesonide.


USE IN SPECIFIC POPULATIONS


PREGNANCY: 

The available data from published case series, epidemiological studies, and
reviews with oral budesonide use in pregnant women have not identified a
drug-associated risk of major birth defects, miscarriage, or other adverse
maternal or fetal outcomes. There are risks to the mother and fetus associated
with IgAN. Infants exposed to in utero corticosteroids, including budesonide,
are at risk for hypoadrenalism.


PLEASE SEE FULL PRESCRIBING INFORMATION.

References: 1. TARPEYO. Prescribing Information. Calliditas Therapeutics AB;
2021. 2. Barratt J, Rovin BH, Cattran D, et al. Why target the gut to treat IgA
nephropathy? Kidney Int Rep. 2020;5(10):1620-1624.
doi:10.1016/j.ekir.2020.08.009 3. Data on file. Calliditas Therapeutics AB. 4.
Fellström BC, Barratt J, Cook H, et al. Targeted-release budesonide versus
placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised,
placebo-controlled phase 2b trial. Lancet. 2017;389(10084):2117-2127.
doi:10.1016/S0140-6736(17)30550-0 5. Chang S, Li X-K. The role of immune
modulation in pathogenesis of IgA nephropathy. Front Med (Lausanne). 2020;7:92.
doi:10.3389/fmed.2020.00092 6. Canetta PA, Kiryluk K, Appel GB. Glomerular
diseases: emerging tests and therapies for IgA nephropathy. Clin J Am Soc
Nephrol. 2014;9(3):617-625. doi:10.2215/CJN.07260713 7. Kiryluk K, Novak J. The
genetics and immunobiology of IgA nephropathy. J Clin Invest.
2014;124(6):2325-2332. doi:10.1172/JCI74475 8. Bhachu JS, Scionti K, Muto M,
Molyneux K, Barratt J. Targeted release- budesonide (Nefecon) modifies
circulating IgA-IgG immune complex levels and levels of poorly O-galactosylated
IgA in IgAN [abstract 0038]. Kidney Dis. 2018;4(3):121-122. 9. Suzuki H, Kiryluk
K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol.
2011;22(10):1795-1803. doi:10.1681/ASN.2011050464 10. Del Vecchio L, Rimoldi C,
Pozzi C. Nefecon (targeted-release formulation-budesonide) for the treatment of
IgA nephropathy. Future Rare Dis. 2021;1(4). doi.org/10.2217/frd-2021-0013 11.
Barratt J, Lafayette R, Kristensen J, et al; NefIgArd Trial Investigators.
Results from part A of the multi-center, double-blind, randomized,
placebo-controlled NefIgArd trial, which evaluated targeted-release formulation
of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney
Int. 2023;103:391-402. https://doi.org/10.1016/j.kint.2022.09.017 12. KDIGO
Clinical Practice Guideline for Glomerulonephritis. June 2012. Accessed June 22,
2023.
https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2012-GN-Guideline-English.pdf
13. Hall YN, Fuentes EF, Chertow GM, Olson JL. Race/ethnicity and disease
severity in IgA nephropathy. BMC Nephrol. 2004;5:10. doi:10.1186/1471-2369-5-10
14. Trachtman H, Nelson P, Adler S, et al. DUET: A phase 2 study evaluating the
efficacy and safety of sparsentan in patients with FSGS [published correction
appears in J Am Soc Nephrol. 2019;30(3):518]. J Am Soc Nephrol.
2018;29(11):2745-2754. doi:10.1681/ASN.2018010091 15. Barratt J, Tumlin JA,
Suzuki Y, et al. 24-week interim analysis of a randomized, double-blind,
placebo-controlled phase 2 study of atacicept in patients with IgA nephropathy
and persistent proteinuria. Abstract presented at: American Society of
Nephrology Kidney Week; October 20-25, 2020; Denver, CO. 16. Thompson A, Carroll
K, Inker LA, et al. Proteinuria reduction as a surrogate end point in trials of
IgA nephropathy. Clin J Am Soc Nephrol. 2019;14(3):469-481.
doi:10.2215/CJN.08600718 17. Barratt J, Feehally J. Primary IgA nephropathy: new
insights into pathogenesis. Semin Nephrol. 2011;31(4):349-360.
doi:10.1016/j.semnephrol.2011.06.006 18. DeSousa- Pereira P, Woof JM. IgA:
structure, function, and developability. Antibodies (Basel). 2019;8(4):57.
doi:10.3390/antib8040057


FIRST FDA-APPROVED TREATMENT TO REDUCE PROTEINURIA IN ADULTS WITH IGA
NEPHROPATHY AT RISK OF RAPID DISEASE PROGRESSION 1


TREAT IGA NEPHROPATHY WHERE IT IS THOUGHT TO ORIGINATE WITH TARPEYO1-4

TARPEYO® is designed to deliver treatment to an area of the ileum to target
mucosal B cells, which are responsible for the production of galactose-deficient
IgA1 antibodies, causing immunoglobulin A Nephropathy (IgAN). Through
anti-inflammatory and immunosuppressive eﬀects at the glucocorticoid receptor,
TARPEYO can modulate B cell numbers and activity.1,2,4

It has not been established to what extent the eﬀicacy of TARPEYO is mediated
via local eﬀects in the ileum vs systemic eﬀects.1



Navigate the pathogenesis of IgAN and treatment with TARPEYO
Dive deeper into efficacy data
Download an enrollment form for TARPEYO Touchpoints
Indication

TARPEYO® is a corticosteroid indicated to reduce proteinuria in adults with
primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease
progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.

This indication is approved under accelerated approval based on a reduction in
proteinuria. It has not been established whether TARPEYO slows kidney function
decline in patients with IgAN. Continued approval for this indication may be
contingent upon verification and description of clinical benefit in a
confirmatory clinical trial.

Important Safety Information


CONTRAINDICATIONS: 

TARPEYO is contraindicated in patients with hypersensitivity to budesonide or
any of the ingredients of TARPEYO. Serious hypersensitivity reactions, including
anaphylaxis, have occurred with other budesonide formulations.

Warnings and Precautions


HYPERCORTICISM AND ADRENAL AXIS SUPPRESSION: 

When corticosteroids are used chronically, systemic effects such as
hypercorticism and adrenal suppression may occur. Corticosteroids can reduce the
response of the hypothalamus-pituitary-adrenal (HPA) axis to stress. In
situations where patients are subject to surgery or other stress situations,
supplementation with a systemic corticosteroid is recommended. When
discontinuing therapy [see Dosing and Administration] or switching between
corticosteroids, monitor for signs of adrenal axis suppression.

Patients with moderate to severe hepatic impairment (Child-Pugh Class B and C,
respectively) could be at an increased risk of hypercorticism and adrenal axis
suppression due to an increased systemic exposure to oral budesonide. Avoid use
in patients with severe hepatic impairment (Child-Pugh Class C). Monitor for
increased signs and/or symptoms of hypercorticism in patients with moderate
hepatic impairment (Child-Pugh Class B).


RISKS OF IMMUNOSUPPRESSION: 

Patients who are on drugs that suppress the immune system are more susceptible
to infection than healthy individuals. Chicken pox and measles, for example, can
have a more serious or even fatal course in susceptible patients or patients on
immunosuppressive doses of corticosteroids. Avoid corticosteroid therapy in
patients with active or quiescent tuberculosis infection; untreated fungal,
bacterial, systemic viral, or parasitic infections; or ocular herpes simplex.
Avoid exposure to active, easily transmitted infections (eg, chicken pox,
measles). Corticosteroid therapy may decrease the immune response to some
vaccines.


OTHER CORTICOSTEROID EFFECTS: 

TARPEYO is a systemically available corticosteroid and is expected to cause
related adverse reactions. Monitor patients with hypertension, prediabetes,
diabetes mellitus, osteoporosis, peptic ulcer, glaucoma, cataracts, a family
history of diabetes or glaucoma, or with any other condition in which
corticosteroids may have unwanted effects.


ADVERSE REACTIONS: 

In clinical studies, the most common adverse reactions with TARPEYO (occurring
in ≥5% of TARPEYO patients and ≥2% higher than placebo) were hypertension (16%),
peripheral edema (14%), muscle spasms (13%), acne (11%), dermatitis (7%), weight
increase (7%), dyspnea (6%), face edema (6%), dyspepsia (5%), fatigue (5%), and
hirsutism (5%).


DRUG INTERACTIONS: 

Budesonide is a substrate for CYP3A4. Avoid use with potent CYP3A4 inhibitors,
such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir,
erythromycin, and cyclosporine. Avoid ingestion of grapefruit juice with
TARPEYO. Intake of grapefruit juice, which inhibits CYP3A4 activity, can
increase the systemic exposure to budesonide.


USE IN SPECIFIC POPULATIONS


PREGNANCY: 

The available data from published case series, epidemiological studies, and
reviews with oral budesonide use in pregnant women have not identified a
drug-associated risk of major birth defects, miscarriage, or other adverse
maternal or fetal outcomes. There are risks to the mother and fetus associated
with IgAN. Infants exposed to in utero corticosteroids, including budesonide,
are at risk for hypoadrenalism.


PLEASE SEE FULL PRESCRIBING INFORMATION.

References: 1. TARPEYO. Prescribing Information. Calliditas Therapeutics AB;
2021. 2. Barratt J, Rovin BH, Cattran D, et al. Why target the gut to treat IgA
nephropathy? Kidney Int Rep. 2020;5(10):1620-1624.
doi:10.1016/j.ekir.2020.08.009 3. Data on file. Calliditas Therapeutics AB. 4.
Fellström BC, Barratt J, Cook H, et al. Targeted-release budesonide versus
placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised,
placebo-controlled phase 2b trial. Lancet. 2017;389(10084):2117-2127.
doi:10.1016/S0140-6736(17)30550-0 5. Chang S, Li X-K. The role of immune
modulation in pathogenesis of IgA nephropathy. Front Med (Lausanne). 2020;7:92.
doi:10.3389/fmed.2020.00092 6. Canetta PA, Kiryluk K, Appel GB. Glomerular
diseases: emerging tests and therapies for IgA nephropathy. Clin J Am Soc
Nephrol. 2014;9(3):617-625. doi:10.2215/CJN.07260713 7. Kiryluk K, Novak J. The
genetics and immunobiology of IgA nephropathy. J Clin Invest.
2014;124(6):2325-2332. doi:10.1172/JCI74475 8. Bhachu JS, Scionti K, Muto M,
Molyneux K, Barratt J. Targeted release- budesonide (Nefecon) modifies
circulating IgA-IgG immune complex levels and levels of poorly O-galactosylated
IgA in IgAN [abstract 0038]. Kidney Dis. 2018;4(3):121-122. 9. Suzuki H, Kiryluk
K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol.
2011;22(10):1795-1803. doi:10.1681/ASN.2011050464 10. Del Vecchio L, Rimoldi C,
Pozzi C. Nefecon (targeted-release formulation-budesonide) for the treatment of
IgA nephropathy. Future Rare Dis. 2021;1(4). doi.org/10.2217/frd-2021-0013 11.
Barratt J, Lafayette R, Kristensen J, et al; NefIgArd Trial Investigators.
Results from part A of the multi-center, double-blind, randomized,
placebo-controlled NefIgArd trial, which evaluated targeted-release formulation
of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney
Int. 2023;103:391-402. https://doi.org/10.1016/j.kint.2022.09.017 12. KDIGO
Clinical Practice Guideline for Glomerulonephritis. June 2012. Accessed June 22,
2023.
https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2012-GN-Guideline-English.pdf
13. Hall YN, Fuentes EF, Chertow GM, Olson JL. Race/ethnicity and disease
severity in IgA nephropathy. BMC Nephrol. 2004;5:10. doi:10.1186/1471-2369-5-10
14. Trachtman H, Nelson P, Adler S, et al. DUET: A phase 2 study evaluating the
efficacy and safety of sparsentan in patients with FSGS [published correction
appears in J Am Soc Nephrol. 2019;30(3):518]. J Am Soc Nephrol.
2018;29(11):2745-2754. doi:10.1681/ASN.2018010091 15. Barratt J, Tumlin JA,
Suzuki Y, et al. 24-week interim analysis of a randomized, double-blind,
placebo-controlled phase 2 study of atacicept in patients with IgA nephropathy
and persistent proteinuria. Abstract presented at: American Society of
Nephrology Kidney Week; October 20-25, 2020; Denver, CO. 16. Thompson A, Carroll
K, Inker LA, et al. Proteinuria reduction as a surrogate end point in trials of
IgA nephropathy. Clin J Am Soc Nephrol. 2019;14(3):469-481.
doi:10.2215/CJN.08600718 17. Barratt J, Feehally J. Primary IgA nephropathy: new
insights into pathogenesis. Semin Nephrol. 2011;31(4):349-360.
doi:10.1016/j.semnephrol.2011.06.006 18. DeSousa- Pereira P, Woof JM. IgA:
structure, function, and developability. Antibodies (Basel). 2019;8(4):57.
doi:10.3390/antib8040057


FOOTER

 * Privacy Policy
 * Terms of Use
 * Contact Us
 * Visit Patient Website
 * Calliditas Therapeutics
 * About Cookies

top

 


YOU ARE NOW LEAVING TARPEYOHCP.COM

The website you are linking to is not owned or controlled by Calliditas
Therapeutics, and Calliditas Therapeutics is not responsible for the content on
this site.

Note: Due to the Sunshine Act, you will need to enter your information to access
this publication. The publication you are linking to includes information that
is not in the full Prescribing Information for TARPEYO.

Please see Indication and Important Safety Information here.

OK CANCEL


NEW INDICATION

 

Now FDA approved based on 2-year study results

See what this approval can mean for your patients

VIEW PRESCRIBING INFORMATION READ OUR PRESS RELEASE

12/23   US-TAR-2300241

Intended for US Healthcare professionals. This site is intended only for US
residents. The products discussed in this site may have different product
labeling in different countries.

TARPEYO is a registered trademark of Calliditas Therapeutics AB, or its
affiliates.

© Calliditas Therapeutics AB
  All rights reserved.   07/23 US-TAR-2300144




THIS WEBSITE USES COOKIES

We use cookies to personalize content and ads, to provide social media features,
and to analyze our traffic. We also share information about your use of our site
with our social media, advertising and analytics partners who may combine it
with other information that you’ve provided to them or that they’ve collected
from other web pages that are not governed by us.

ACCEPT DECLINE
tarpeyohcpprod.prod.acquia-sites.com Open in urlscan Pro 3.231.20.35 Public Scan

Form analysis 0 forms found in the DOM

Text Content

tarpeyohcpprod.prod.acquia-sites.com Open in urlscan Pro
3.231.20.35 Public Scan

Form analysis
0 forms found in the DOM
